Ruth N. Moro

1.4k total citations
20 papers, 853 citations indexed

About

Ruth N. Moro is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Ruth N. Moro has authored 20 papers receiving a total of 853 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 10 papers in Epidemiology and 5 papers in Surgery. Recurrent topics in Ruth N. Moro's work include Tuberculosis Research and Epidemiology (14 papers), Pneumocystis jirovecii pneumonia detection and treatment (5 papers) and Pneumonia and Respiratory Infections (4 papers). Ruth N. Moro is often cited by papers focused on Tuberculosis Research and Epidemiology (14 papers), Pneumocystis jirovecii pneumonia detection and treatment (5 papers) and Pneumonia and Respiratory Infections (4 papers). Ruth N. Moro collaborates with scholars based in United States, Spain and Uganda. Ruth N. Moro's co-authors include Margarita E. Villarino, Andrey Borisov, Marc Weiner, Stefan Goldberg, Timothy R. Sterling, Nigel Scott, Andrew Vernon, Stephen E. Weis, Nong Shang and Marcus Barreto Conde and has published in prestigious journals such as Annals of Internal Medicine, American Journal of Respiratory and Critical Care Medicine and Clinical Infectious Diseases.

In The Last Decade

Ruth N. Moro

19 papers receiving 831 citations

Peers

Countries citing papers authored by Ruth N. Moro

Since Specialization

Citations

This map shows the geographic impact of Ruth N. Moro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth N. Moro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth N. Moro more than expected).

Fields of papers citing papers by Ruth N. Moro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth N. Moro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth N. Moro. The network helps show where Ruth N. Moro may publish in the future.

Co-authorship network of co-authors of Ruth N. Moro

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth N. Moro. A scholar is included among the top collaborators of Ruth N. Moro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth N. Moro. Ruth N. Moro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-Like Reactions During Treatment of Latent Tuberculosis Infection 2024 ·The Journal of Infectious Diseases ·Ruth N. Moro, Carolina Mehaffy, Prithwiraj De, Elizabeth Phillips, Andrey Borisov, Timothy R. Sterling, Karen M. Dobos	0
2	Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine 2023 ·Contemporary Clinical Trials ·Nigel Scott, (unknown), Andrew Vernon, (unknown), Karlyn D. Beer, (unknown), Joan A. Caylà, Michael Chen, Pei-Jean Feng, Ruth N. Moro, David P. Holland, Neil Martinson, Joan-Pau Millet, José M. Miró, Robert Belknap	3
3	Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection 2023 ·Clinical Infectious Diseases ·(unknown), Robert Belknap, David P. Holland, Ruth N. Moro, Michael P. Chen, (unknown), (unknown), Joan A. Caylà, Nigel Scott, Andrey Borisov, Neel R. Gandhi	7
4	US emergency department visits for acute harms from over‐the‐counter cough and cold medications, 2017–2019 2021 ·Pharmacoepidemiology and Drug Safety ·(unknown), Maribeth C. Lovegrove, Ruth N. Moro, Andrew I. Geller, Nina J. Weidle, Jennifer N. Lind, Daniel S. Budnitz	2
5	Emergency Department Visits Attributed to Adverse Events Involving Benzodiazepines, 2016–2017 2020 ·American Journal of Preventive Medicine ·Ruth N. Moro, Andrew I. Geller, Nina J. Weidle, Jennifer N. Lind, Maribeth C. Lovegrove, Kathleen Rose, (unknown), Jana McAninch, Deborah Dowell, Daniel S. Budnitz	14
6	Assessment of ICD‐10‐CM code assignment validity for case finding of outpatient anticoagulant‐related bleeding among Medicare beneficiaries 2019 ·Pharmacoepidemiology and Drug Safety ·Nadine Shehab, Robert Ziemba, (unknown), Andrew I. Geller, Ruth N. Moro, Brian F. Gage, Daniel S. Budnitz, (unknown)	27
7	Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials 2018 ·Annals of the American Thoracic Society ·Ruth N. Moro, Nigel Scott, Andrew Vernon, Naomi K. Tepper, Stefan Goldberg, Kevin Schwartzman, Chi Chiu Leung, Neil W. Schluger, Robert Belknap, Richard E. Chaisson, Masahiro Narita, Elizabeth S. Machado, Marta López, Jorge Sánchez, Margarita E. Villarino, Timothy R. Sterling	42
8	Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis 2018 ·American Journal of Preventive Medicine ·Gibril J. Njie, Sapna Bamrah Morris, Rachel Yelk Woodruff, Ruth N. Moro, Andrew Vernon, Andrey Borisov	55
9	Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection 2017 ·Annals of Internal Medicine ·Robert Belknap, David P. Holland, Pei-Jean Feng, Joan-Pau Millet, Joan A. Caylà, Neil Martinson, (unknown), (unknown), Ruth N. Moro, Nigel Scott, (unknown), José M. Miró, Margarita E. Villarino, Marc Weiner, Andrey Borisov	103
10	High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection 2017 ·Clinical Infectious Diseases ·Amy L. Sandul, (unknown), (unknown), Mark N. Lobato, Suzanne M. Marks, Risa M. Webb, Shuhua Wang, Brock Stewart, (unknown), (unknown), Neha Shah, Asween Marco, Naveen Patil, (unknown), Ruth N. Moro, John Jereb, Sundari Mase, Terence Chorba, (unknown), Christine Ho	69
11	Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial 2017 ·The International Journal of Tuberculosis and Lung Disease ·Ruth N. Moro, Timothy R. Sterling, Jussi Saukkonen, Andrew Vernon, C. Robert Horsburgh, Richard E. Chaisson, Carol Hamilton, Margarita E. Villarino, Stefan Goldberg	10
12	Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada 2016 ·Clinical Infectious Diseases ·Ruth N. Moro, Andrey Borisov, Jussi Saukkonen, Awal Khan, Timothy R. Sterling, Margarita E. Villarino, Nigel Scott, Nong Shang, Amy Kerrigan, Stefan Goldberg	33
13	Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study 2015 ·Clinical Infectious Diseases ·Timothy R. Sterling, Ruth N. Moro, Andrey Borisov, Elizabeth Phillips, Gillian Shepherd, N. F. Adkinson, Stephen E. Weis, Christine Ho, Margarita E. Villarino	80
14	Treatment for Preventing Tuberculosis in Children and Adolescents 2015 ·JAMA Pediatrics ·Margarita E. Villarino, Nigel Scott, Stephen E. Weis, Marc Weiner, Marcus Barreto Conde, Brenda Jones, Sharon Nachman, Ricardo Oliveira, Ruth N. Moro, Nong Shang, Stefan Goldberg, Timothy R. Sterling	145
15	Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial 2014 ·American Journal of Respiratory and Critical Care Medicine ·Susan E. Dorman, Radojka M. Savić, Stefan Goldberg, Jason E. Stout, Neil W. Schluger, Grace Muzanyi, John L. Johnson, Payam Nahid, Emily J. Hecker, Charles M. Heilig, Lorna Bozeman, (unknown), Ruth N. Moro, William R. Mac Kenzie, Kelly E. Dooley, Eric Nuermberger, Andrew Vernon, Marc Weiner	76
16	Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium 2012 ·The Journal of Infectious Diseases ·Susan E. Dorman, Stefan Goldberg, Jason E. Stout, Grace Muzanyi, John L. Johnson, Marc Weiner, Lorna Bozeman, Charles M. Heilig, (unknown), Ruth N. Moro, Masahiro Narita, Payam Nahid, Susan M. Ray, (unknown), Beliyou Haile, Eric Nuermberger, Andrew Vernon, Neil W. Schluger	85
17	High Prevalence of Persistent Parasitic Infections in Foreign-Born, HIV-Infected Persons in the United States 2011 ·PLoS neglected tropical diseases ·Natasha S. Hochberg, Ruth N. Moro, Anandi N. Sheth, Susan P. Montgomery, Frank Steurer, Isabel McAuliffe, Yun F. Wang, Wendy S. Armstrong, Hilda N. Rivera, Jeffrey L. Lennox, Carlos Franco‐Paredes	34
18	A Phase II Study Of A Rifapentine-Containing Regimen For Intensive Phase Treatment Of Pulmonary Tuberculosis: Preliminary Results For Tuberculosis Trials Consortium Study 29 2011 ·Susan E. Dorman, Stefan Goldberg, (unknown), Charles M. Heilig, Jason E. Stout, Neil W. Schluger, Ruth N. Moro, Lorna Bozeman, John L. Johnson, Grace Muzanye, Payam Nahid, Masahiro Narita, Susan M. Ray, (unknown), (unknown), Marc Weiner, Andrew Vernon	6
19	Cystic echinococcosis in a rural Peruvian family 2002 ·Annals of Tropical Medicine and Parasitology ·Pedro L. Moro, Ruth N. Moro, Luis Poggi, Robert H. Gilman	3
20	A Placebo‐Controlled Crossover Trial of Nimodipine in Pediatric Migraine 1990 ·Headache The Journal of Head and Face Pain ·P. A. Battistella, (unknown), Ruth N. Moro, (unknown), Silvio Bertoli, (unknown), (unknown)	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact